HIGH POTENCY APIS
Engineering alone is insufficient, however. Regulators are increasingly scrutinising cleaning validation and the risk of cross-contamination in multi-purpose facilities.
To meet these standards, CDMOs are employing high-sensitivity analytical techniques like liquid chromatography-mass spectrometry( LC-MS) to detect and quantify carry-over at the nanogram level. Furthermore, specialised in-house training protocols have become essential, as handling these materials requires a level of‘ containment culture’ that goes beyond simple PPE.
To optimise yields and reduce the high costs associated with HPAPI production, CDMOs are adopting Industry 4.0 tools faster than many innovator pharmaceutical companies. Artificial intelligence( AI) is being used for reaction optimisation, identifying the‘ golden batch’ by analysing historical process data to reduce impurities and energy consumption; and predictive maintenance, using sensors to detect process deviations before they lead to batch failure.
Likewise, continuous manufacturing may replace traditional batch processes, particularly for highenergy chemistry used in building blocks for APIs. The benefits include safety, because smaller quantities of potent material are‘ in process’ at any given time, significantly limiting exposure risk; yield improvements of 10 – 30 %: and reducing cycle times from weeks to days.
Sustainability & resilience
As we look toward 2030, the HPAPI market will be defined by two key pillars: environmental, social and governance( ESG) compliance and supply chain diversification.
While HPAPI production is inherently energy-intensive, the adoption of enzymatic synthesis and alternative solvents is helping reduce step counts and solvent waste. Embracing these green practices is no longer just an ethical choice; it is becoming a critical differentiator in CDMO selection for ESG-conscious pharmaceutical firms.
To expand on the role of green chemistry in HPAPI manufacturing, it is essential to move beyond general sustainability and look at the technical molecular engineering that makes these processes possible. In 2026, CDMOs like Piramal are transitioning from a reactive waste management mindset to a proactive’ Greenness by Design’ framework.
The most significant advancement is the integration of sustainability at the discovery stage rather than during scale-up. Piramal’ s‘ Bridge’ framework evaluates key parameters and scale-dependent sensitivities early in development to avoid bottlenecks and costly redesigns later. By embedding environmental responsibility into hit-to-lead and lead optimisation, chemists can proactively design synthetic routes that are inherently safer and more efficient.
Meanwhile, biocatalysis has shifted from a last resort to a primary strategy for HPAPIs. Its advantages in high-potency manufacturing are multi-fold. Enzymes’ high regio- and enantioselectivity are critical for complex, chiral HPAPIs. This eliminates the need for multiple protection and deprotection steps, significantly shortening synthetic routes.
Unlike traditional chemocatalysis, biocatalytic reactions typically occur at ambient pressure and
near-ambient temperature. This reduces energy consumption and the need for expensive, high-pressure reaction vessels. Finally, biocatalysts can replace scarce and toxic precious metals like rhodium, which often require complex and wastegenerating removal processes.
Advanced solvent replacement and recovery is crucial because solvents account for the vast majority of waste in API production— often tens to hundreds of kg / kg of product. The 2026 standard for CDMOs involves:
• Replacing toxic or ozonedepleting solvents such as dichloromethane( DCM), tetrahydrofuran( THF), and N, Ndimethylformamide( DMF) with safer alternatives like ethanol, water, or bio-renewable solvents like 2-MeTHF
• Solvent repurposing with onsite distillation columns and recovery systems that allow for the reuse of solvents like acetonitrile and methanol, cutting both procurement costs and disposal impact
• Using supercritical CO 2
, a chemically inert, non-toxic and low-cost green solvent to solubilise poorly soluble APIs and remove impurities
Modern CDMOs also use AI-driven tools( such as Smart PMI) to set molecule-aware targets, driving innovations that have reduced solvent use by up to 85 % and waste management costs by up to 40 % in some cases. Computational tools like Saturn-RXN( an AI-driven generative molecular design framework) allow chemists to bring sustainability constraints directly into the discovery phase. This ensures that‘ greenness’ is balanced with speed and quality from the very first reaction model.
Fully integrated ADC services
FIII / Flnl1h
JUL / AUG 2026 SPECCHEMONLINE. COM
29